Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 17, 2021 - Issue 7
Submit an article Journal homepage
2,730
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries

Prashant Kumara Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USAView further author information
,
Ravi S. Shuklaa Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USAView further author information
,
Ashaben Patela Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USAView further author information
,
Swathi R. Pullagurlaa Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USAView further author information
,
Christopher Birda Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USAView further author information
,
Oluwadara Oguna Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USAView further author information
,
Ozan S. Kumrua Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USAView further author information
,
Ahd Hamidib Batavia Biosciences B.V., Bioscience Park Leiden, Leiden, The NetherlandsView further author information
,
Femke Hoeksemab Batavia Biosciences B.V., Bioscience Park Leiden, Leiden, The NetherlandsView further author information
,
Christopher Yallopb Batavia Biosciences B.V., Bioscience Park Leiden, Leiden, The NetherlandsView further author information
,
Julie E. Binesc Murdoch Children’s Research Institute, Department of Paediatrics, University of Melbourne, Parkville, Australia;d Department of Gastroenterology and Clinical Nutrition, Royal Children’s Hospital, Parkville, AustraliaView further author information
,
Sangeeta B. Joshia Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USACorrespondence[email protected]
View further author information
&
David B. Volkina Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USACorrespondence[email protected]
View further author information
 show all
Pages 2298-2310 | Received 01 Oct 2020, Accepted 29 Jan 2021, Published online: 16 Apr 2021

References

  • Tate JE, Burton AH, Boschi-Pinto C, Parashar UD. World Health Organization-coordinated global rotavirus surveillance N. global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000–2013. Clin Infect Dis. 2016;62(2):S96–S105. doi:10.1093/cid/civ1013.
  • World Health Organization. WHO recommends use of rotavirus vaccines in all national immunization programmes. [ accessed 2020 Sept 23]. http://www.who.int/immunization/newsroom/newsstory_rotavirus_vaccines_immunization_programmes/en/.
  • Parashar UD, Johnson H, Steele AD, Tate JE. Health impact of rotavirus vaccination in developing countries: progress and way forward. Clin Infect Dis. 2016;62(2):S91–S95. doi:10.1093/cid/civ1015.
  • Bines JE, At Thobari J, Satria CD, Handley A, Watts E, Cowley D, Nirwati H, Ackland J, Standish J, Justice F, et al. Human neonatal rotavirus vaccine (RV3-BB) to target rotavirus from birth. N Engl J Med. 2018;378:719–30. doi:10.1056/NEJMoa1706804.
  • Cherian T, Wang S, Mantel C. Rotavirus vaccines in developing countries: the potential impact, implementation challenges, and remaining questions. Vaccine. 2012;30S:A3–A6. doi:10.1016/j.vaccine.2011.10.007.
  • Das JK, Bhutta ZA. Global challenges in acute diarrhea. Curr Opin Gastroenterol. 2016;32:18–23. doi:10.1097/MOG.0000000000000236.
  • International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub. [ accessed 2020 Sept 23]. www.view-hub.org.
  • Centers for Disease Control and Prevention. Rotavirus Vaccination. [ accessed 2020 Sept 23]. https://www.cdc.gov/vaccines/vpd/rotavirus/index.html.
  • World Health Organization. WHO prequalified vaccines. [ accessed 2020 Sept 23]. https://extranet.who.int/gavi/PQ_Web/.
  • Burke CJ, Volkin DB. Rotavirus vaccine formulations. United States Patent number US 6,616,931 469 B1. 2000.
  • Vincent VV. Live attenuated rotavirus vaccine for oral administration. United States Patent number US 8,192,747 B2. 2006.
  • Zaman K. Rotavirus vaccine: a promise for the future. J Health Popul Nutr. 2008;26(4):385–87. doi:10.3329/jhpn.v26i4.1879.
  • Kirkwood CD, Ma LF, Carey ME, Steele AD. The rotavirus vaccine development pipeline. Vaccine. 2019;37(50):7328–35. doi:10.1016/j.vaccine.2017.03.076.
  • Ward RL, Bernstein DI. Rotarix: a rotavirus vaccine for the world. Clin Infect Dis. 2009;48(2):222–28. doi:10.1086/595702.
  • Vadrevu KM, Prasad SD. Rotavirus vaccine compositions and process for preparing the same. United States Patent number US 2015/0098967 A1. 2013.
  • Boniface K, Byars SG, Cowley D, Kirkwood CD, Bines JE. Human neonatal rotavirus vaccine (RV3-BB) produces vaccine take irrespective of histo-blood group antigen status. J Infect Dis. 2020;221:1070–78. doi:10.1093/infdis/jiz333.
  • Bishop RF. Development of candidate rotavirus vaccines. Vaccine. 1993;11(2):247–54. doi:10.1016/0264-410x(93)90025-s.
  • Clark A, Sanderson C. Timing of children’s vaccinations in 45 low-income and middle-income countries: an analysis of survey data. Lancet. 2009;373(9674):1543–49. doi:10.1016/S0140-6736(09)60317-2.
  • Lloyd-Johnsen C, Justice F, Donath S, Bines JE. Retrospective hospital based surveillance of intussusception in children in a sentinel paediatric hospital: benefits and pitfalls for use in post-marketing surveillance of rotavirus vaccines. Vaccine. 2012;30(1):A190–195. doi:10.1016/j.vaccine.2011.11.015.
  • Kumar P, Pullagurla SR, Patel A, Shukla RS, Bird C, Kumru OS, Hamidi A, Hoeksema F, Yallop C, Bines JE, et al. Effect of formulation variables on the stability of a live, rotavirus (RV3-BB) vaccine candidate using in vitro gastric digestion models to mimic oral delivery. J Pharm Sci. 2021;110:760–70. doi:10.1016/j.xphs.2020.09.047.
  • Arnold M, Patton JT, McDonald SM. Culturing, storage, and quantification of rotaviruses. Curr Protoc Microbiol. 2009;Chapter 15:Unit 15C 3. doi:10.1002/9780471729259.mc15c03s15.
  • Todd Ranheim PKM, Mathis PK, Joelsson DB, Smith ME, Campbell KM, Lucas G, Barmat S, Melissen E, Benz R, Lewis JA, et al. Development and application of a quantitative RT-PCR potency assayfor a pentavalent rotavirus vaccine (RotaTeq®). J Virol Methods. 2006;131(2):193–201. doi:10.1016/j.jviromet.2005.08.013.
  • Menard O, Bourlieu C, De Oliveira SC, Dellarosa N, Laghi L, Carriere F, Capozzi F, Dupont D, Deglaire A. A first step towards a consensus static in vitro model for simulating full-term infant digestion. Food Chem. 2018;240:338–45. doi:10.1016/j.foodchem.2017.07.145.
  • Yang DP, Goldberg KM, Ma XD, Magargle W, Rappaport R. Development of a fluorescent focus identification assay using serotype-specific monoclonal antibodies for detection and quantitation of rotaviruses in a tetravalent rotavirus vaccine. Clin Diagn Lab Immunol. 1998;5(6):780–83. PMID: 9801334. doi:10.1128/CDLI.5.6.780-783.1998.
  • Ranheim T, Mathis PK, Joelsson DB, Smith ME, Campbell KM, Lucas G, Barmat S, Melissen E, Benz R, Lewis JA, et al. Development and application of a quantitative RT-PCR potency assay for a pentavalent rotavirus vaccine (RotaTeq). J Virol Methods. 2006;131(2):193–201. doi:10.1016/j.jviromet.2005.08.013.
  • Laerd Statistics. Pearson product-moment correlation. [ accessed 2020 Sept 23]. https://statistics.laerd.com/statistical-guides/pearson-correlation-coefficient-statistical-guide.php.
  • Ditter D, Mahler HC, Roehl H, Wahl M, Huwyler J, Nieto A, Allmendinger A. Characterization of surface properties of glass vials used as primary packaging material for parenterals. Eur J Pharm Biopharm. 2018;125:58–67. doi:10.1016/j.ejpb.2017.12.018.
  • Pullagurla SR, Kumar P, Ogun O, Kumru OS, Hamidi A, Hoeksema F, Yallop C, Bines JE, Volkin DB, Joshi SB. Modeling the long-term stability profiles of a live, rotavirus (RV3-BB) vaccine candidate in various liquid formulations via extrapolations of real-time and accelerated stability data. (manuscript in preparation).
  • Schofield TL. Vaccine stability study design and analysis to support product licensure. Biologicals. 2009;37(6):387–96. doi:10.1016/j.biologicals.2009.08.009.
  • Hamidi A, Hoeksema F, Velthof P, Lemckert A, Gillissen G, Luitjens A, Bines JE, Pullagurla SR, Kumar P, Volkin DB, et al. Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine. Submitted 2020.
  • Formulation development of a stable, orally delivered live human neonatal Rotavirus (RV3-BB) vaccine candidate. Vaccine technology VII. [ accessed 2020 Sept 23]. http://dc.engconfintl.org/vt_vii/24/.
  • Bines JE, Danchin M, Jackson P, Handley A, Watts E, Lee KJ, West A, Cowley D, Chen MY, Barnes GL, et al. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2015;15(12):1389–97. doi:10.1016/S1473-3099(15)00227-3.
  • Tissera MS, Cowley D, Bogdanovic-Sakran N, Hutton ML, Lyras D, Kirkwood CD, Buttery JP. Options for improving effectiveness of rotavirus vaccines in developing countries. Hum Vaccin Immunother. 2017;13(4):921–27. doi:10.1080/21645515.2016.1252493.
  • Chan J, Nirwati H, Triasih R, Bogdanovic-Sakran N, Soenarto Y, Hakimi M, Duke T, Buttery JP, Bines JE, Bishop RF, et al. Maternal antibodies to rotavirus: could they interfere with live rotavirus vaccines in developing countries? Vaccine. 2011;29(6):1242–47. doi:10.1016/j.vaccine.2010.11.087.
  • U.S. National Library of medicine. A phase II dose-ranging study of oral RV3-BB rotavirus vaccine. [ accessed 2020 Sept 23]. https://clinicaltrials.gov/ct2/show/record/NCT03483116.
  • U.S. National Library of medicine. Immunogenicity and safety of rotavirus RV3 vaccine (bio farma) in neonates. [ accessed 2020 Sept 23]. https://clinicaltrials.gov/ct2/show/record/NCT04185545
  • Danchin M, Kirkwood CD, Lee KJ, Bishop RF, Watts E, Justice FA, Clifford V, Cowley D, Buttery JP, Bines JE. Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine. Vaccine. 2013;31(23):2610–16. doi:10.1016/j.vaccine.2013.04.008.
  • Kamerzell TJ, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB. Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev. 2011;63(13):1118–59. doi:10.1016/j.addr.2011.07.006.
  • Estes MK, Graham DY, Smith EM, Gerba CP. Rotavirus stability and inactivation. J Gen Virol. 1979;43(2):403–09. doi:10.1099/0022-1317-43-2-403.
  • Desselberger U, Richards J, Tchertanov L, Lepault J, Lever A, Burrone O, Cohen J. Further characterisation of rotaviruscores: ss(+)RNAs can be packaged in vitro but packaging lacks sequence specificity. Virus Res. 2013;178(2):252–63. doi:10.1016/j.virusres.2013.09.034.
  • Madan M, Sikriwal D, Sharma G, Shukla N, Mandyal AK, Kale S, Gill D. Rational design of heat stable lyophilized rotavirus vaccine formulations. Hum Vaccin Immunother. 2018;14(9):2132–41. doi:10.1080/21645515.2018.1487499.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.